top of page
YES_edited_edited.jpg

OUR MISSION

To fund Australia’s brightest and most innovative medical researchers and clinicians in their efforts to provide all cancer patients with Precision cancer treatments and to help create access to new techniques and integrated comprehensive data for medical researchers and physicians.

Dr. Belinda Yeo

Clinician Scientist, Olivia Newton-John Cancer Research Institute

OUR ASPIRATION

To ensure precision treatment for ALL new cancer patients, whatever the cancer, regardless of location, age, income or status. It is our vision that patients are offered the right treatment, first time, every time. And that, at the cusp of a post-genome revolution, Australia can show the world how Precision Medicine is done.

PRECISION MEDICINE
THE RIGHT TREATMENT FOR EVERY CANCER PATIENT

Every cancer is different for every body. Precision Medicine, using current, widely available technologies, offers the tantalising prospect of analysing a tissue sample and treating cancer with the right drug, first time, every time. This increases positive treatment outcomes, decreases treatment times and saves countless millions on ineffective treatments. The data from each sample also helps us further map cancer genetically.

Prof. David Thomas
Director Centre for Molecular Oncology, School of Biomedical Sciences, Uni. of NSW; CEO Omico (Australian Genomic Cancer Medicine Centre); Laboratory Head Genomic Cancer Medicine, Garvan Institute of Medical Research

WDTMG

HERE ARE THE INCREDIBLE CANCER VANQUISHING PROJECTS WE SUPPORT. 

2013 - extant

THE CONNIE JOHNSON BREAST CANCER RESEARCH LABORATORY

INSTITUTION:  The Garvan Institute of Medical Research

CHIEF RESEARCHERS:  Assoc. Prof. Elgene Lim & Assoc. Prof. Alex Swarbrick

SYNOPSIS:  The Connie Johnson Laboratory performs clinically focused laboratory research, aiming to better understand the heterogeneity in breast cancer, and identifying novel ways to treat breast cancer.

READ MORE...

Artboard 35 copy 5.png

2022 - 2025

MoST RURAL AND REGIONAL EXPANSION: OMICO AND THE AUSTRALIAN GENOMIC CANCER MEDICINE PROGRAM

INSTITUTION:  The Garvan Institute of Medical Research & OMICO

CHIEF RESEARCHERS:  Prof. David Thomas & Dr Mandy Ballinger

SYNOPSIS:  The Molecular Screening and Therapeutics (MoST) program uses molecular screening techniques to build genomic profiles of cancers from patients with limited treatment options.

READ MORE...

Artboard 2 copy 5.png
Artboard 2 copy 4.png
Artboard 35 copy.png

2023 - 2026

UTILISING THE LATEST TECHNOLOGIES TO SHED LIGHT ON THE COMPLEX DYNAMIC BETWEEN GENOTYPE AND PHENOTYPE

INSTITUTION:  Children's Cancer Institute

CHIEF RESEARCHERS:  Rob Salomon & Assoc. Prof. Paul Ekbert & Assoc. Prof.Mark Crowley

SYNOPSIS:  The development of minimally invasive tests that monitor disease progression in children and young adults and guides the subsequent change of treatment.

READ MORE...

Artboard 2 copy 15.png
Artboard 35 copy 2.png

2023 - 2026

IMPROVING CANCER OUTCOMES IN RURAL AND REMOTE AUSTRALIA

INSTITUTION:  Macquarie University

CHIEF RESEARCHERS:  Prof. Howard Gurney; Nicola Chapman; A/Prof. Boe Rambaldini; Dr. Kylie Gwynne

SYNOPSIS:  Improving cancer outcomes in rural and remote Australia: developing effective, sustainable and scalable models for clinical trials.

 

READ MORE...

Macquarie.png
Artboard 35 copy 3.png

2023 - 2026

THE ZERO CHILDHOOD CANCER PROGRAM

INSTITUTION:  An initiative of Children’s Cancer Institute and Kids Cancer Centre at Sydney Children’s Hospital

CHIEF RESEARCHERS:  Prof. Glenn Marshall AM

SYNOPSIS:  The Zero Childhood Cancer program aims to one day be able to provide a personalised treatment plan for every child.

 

READ MORE...

Artboard 2 copy 11.png
Artboard 2 copy 12.png
Artboard 35 copy 6.png

2020 - 2025

SHARE, COLLABORATE & CURE: THE MACQUARIE UNIVERSITY CANCER BIOBANK

INSTITUTION:  Macquarie University

CHIEF RESEARCHERS:  Dr. Helen Rizos

SYNOPSIS:  A bold plan to provide a library of viable cancer specimens and genomic data across many cancer types.

 

READ MORE...

Macquarie.png

2020 - 2023

CURING THE INCURABLE: PATIENT-CENTRED DIAGNOSTICS GUIDING THE SELECTION OF THERAPIES FOR METASTATIC BREAST CANCER

Olivia Newton-John Cancer Research Institute (ONJCRI) & La Trobe University

2021 - 2023

PRECISION TARGETING OF BREAST CANCER FIBROSIS TO BOOST EFFICIENCY OF CHEMOTHERAPY

The Garvan Institute of Medical Research

2021 - 2023

MORE PRECISE RISK ESTIMATES FOR EARLY-STAGE BREAST CANCER

The University of Melbourne/Peter MacCallum Cancer Centre

2021 - 2023

IDENTIFYING TARGETS ON MYELOID CELLS TO DESIGN PERSONALISED COMBINATION IMMUNOTHERAPIES FOR TRIPLE-NEGATIVE BREAST CANCER

Olivia Newton-John Cancer Research Institute (ONJCRI) & La Trobe University

2021 - 2023

A NEW IMMUNOTHERAPY APPROACH TO TARGET TRIPLE-NEGATIVE BREAST CANCER

Queensland Institute of Medical Research Berghofer

2020 - 2023

OVERCOMING NETWORK REMODELLING TO IDENTIFY NEW THERAPEUTIC STRATEGIES FOR POOR PROGNOSIS BREAST CANCER

Monash University

2020 - 2023

USING POLYGENIC RISK MODIFICATION TO IMPROVE BREAST CANCER PREVENTION: THE PRIMO TRIAL.

Peter MacCallum Cancer Centre

2019 - 2022

FULL-TIME RESEARCH ASSISTANT FOR A THREE-YEAR PERSONALISED BREAST CANCER RESEARCH PROJECT

Olivia Newton-John Cancer Research Institute (ONJCRI)

2019 - 2020

STOPPING CANCER CELLS’ PRO-SURVIVAL MECHANISMS IN TRIPLE-NEGATIVE BREAST CANCER

The University of Sydney

2019 - 2021

COMBATING AGGRESSIVE BREAST CANCER WITH A NEW TREATMENT

Olivia Newton-John Cancer Research Institute (ONJCRI)

2019 - 2020

DEVELOPING PERSONALISED TREATMENTS FOR BREAST CANCERS WITH POOR PROGNOSIS

Monash University

Artboard 31v2.png
bottom of page